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Cannabis Impairment in the Workplace: A Jurisdictional Analysis of 
Drug Testing Policies and Recommendations in the Context of 
Canadian Legalization and Regulation  
Introduction 
The Government of Canada proposed legislation in April 2017 that, once passed, will 
legalize and regulate cannabis in Canada by July 20181. The intention behind this shift in drug 
policy is to better reflect public health evidence that cannabis prohibition is not effective at 
restricting drug use and is associated with social injustices that target marginalized populations2. 
The proposed Cannabis Act aims to control the production, distribution, sale, and possession of 
cannabis to balance the harms of problematic cannabis use with the social harms of drug 
prohibition3. 
One of the stated goals of the move towards cannabis legalization is the protection of 
public safety2. Cannabis, like other drugs such as alcohol or some prescription medications, can 
cause impairment that can affect an individual’s ability to perform certain tasks safely, such as 
driving4. As a result, the proposed Cannabis Act incorporates a strengthened legal framework for 
identifying and persecuting drivers who are impaired by cannabis, including the use of objective 
(biological) measures for the identification of impaired drivers and graded penalties that reflect 
the level of impairment, similar to the approach towards alcohol-impaired driving5. 
Cannabis impairment can also affect safety in the workplace. However, the proposed 
Cannabis Act does not include a framework for cannabis impairment in the workplace, as 
workplace health and safety in Canada is a provincial jurisdiction for most industries. In British 
Columbia, workplace health and safety is regulated by the Occupational Health and Safety 
Regulations (OHSR)6 under the Workers Compensation Act (WCA)7. Part 4 – General 
3 
 
Conditions of the OHSR contains regulations for impairment in the workplace in sections 4.19 
and 4.208,9. These regulations emphasize the employee’s duty to report any impairment that 
could put their own safety or that of other workers at risk, and the employer/supervisor’s 
responsibility to not knowingly permit a person who is impaired and may endanger themselves 
or others to remain at the workplace8,9. 
However, the presence of these regulations does not necessarily translate into the risk of 
cannabis impairment in the workplace being reduced in practice. The implementation of this 
policy approach relies on individuals having to report use of a drug which has historically been 
criminalized, and may continue to face stigmatization even after legalization occurs. 
Additionally, cannabis impairment is more complex than other impairing substances such as 
alcohol, and may not be well enough understood by workers or employers for them to identify 
when and individual’s cannabis use may affect their safety at work. While objective drug testing 
based on analysis of bodily fluids is a growing field of research in the context of driving and 
workplace impairment, the methods for detecting cannabis impairment are still being developed, 
and the use of the wrong methods have the consequence of punishing individuals for non-
problematic cannabis use rather than the act of performing and activity such as driving or 
working while impaired. 
Purpose 
 In Canada, cannabis is currently a hot topic – with the age of legalization and regulation 
looming nearer, there is (often heated) public debate about the risks of cannabis, and there is 
growing concern by employers who are uncertain of how to deal with cannabis in their 
workplace. This paper argues that while cannabis impairment does indeed pose some risk if it 
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occurs while workers are on the job, a zero-tolerance approach to cannabis in workers is 
unrealistic, perpetuates social harms, and is ineffective at protecting worker safety. Because of 
this, a balance needs to be achieved in a policy approach to workplace drug testing which 
manages both the human rights issues of drug testing as well as protects worker safety. 
This paper will: 
1. Discuss the social context of cannabis as it relates to drug prohibition 
2. Review literature on our current understanding of cannabis impairment  
3. Compare workplace drug testing policies in the context of social harms and workplace 
safety in three jurisdictions 
4. Provide recommendations for workplace drug policies for cannabis which effectively 
incorporate principles of human rights as well as worker safety 
Literature Review 
The Social Context of Cannabis 
 Cannabis legalization and regulation is always a matter of intense public discussion, and 
the same has been true of the discussion taking place in Canada. As much as it is important to 
have a drug policy that is informed by scientific and other forms of evidence, it is also true that 
the push for cannabis legalization has been driven by social movements around the world. 
Understanding the goals of these social movements in pushing for legalization and how the 
future framework of legalization and regulation is attempting to meet those goals requires an 
understanding of the history of cannabis prohibition – and while it is beyond the scope of this 
paper to provide an entire history (there are many other excellent resources that do this10), it is 
discussed briefly in the Canadian context as it essential to understanding why it is important that 
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any policies relating to cannabis legalization, including workplace testing policies, need to 
consider human rights. 
 Cannabis, despite being used for spiritual and medical purposes in various cultures 
throughout human history, was not widely known or used in North America besides for a few 
medical purposes. Despite this, when the United States began its national campaign against drugs 
in the 20th Century, it included cannabis in its ‘war against drugs’, calling it by its Mexican name 
marihuana to add a dangerous foreignness to the plant. The United States’ strict stance on drug 
prohibition was soon taken up in Canada and across the globe10. 
 While the stated goal of the ‘war on drugs’ was to put an end to drug use, in practice, 
criminalizing drug use had many social consequences. Individuals who use drugs are more likely 
to belong to social and racial minorities11, and the war on drugs meant that these people were 
intensely persecuted for relatively minor crimes such as drug possession.  
 Cannabis prohibition is just part of the wider social stigma on drug use which has 
dominated much of drug policy in the 20th Century. However, the tide is changing. Research is 
showing that drug prohibition is not effective at reducing drug use, and that drug use, rather than 
being a dangerous activity that must be eliminated, is an activity that is much more nuanced11. 
While it is true some drugs can be incredibly risky to an individual (such as the recent fentanyl 
overdose epidemic), there are also many instances where drug use can be managed and done 
safely. In essence, drug use can be viewed as a spectrum, encompassing both beneficial uses to 
problematic or harmful uses, as shown in Figure 1. Research supports what those who use 
cannabis have known for decades – that cannabis is not the incredibly dangerous and impairing 
drug that the government has said it is. 
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           Figure 1: Drug use can be understood as a spectrum, with effects ranging from beneficial 
           to problematic. Original diagram from the British Columbia Ministry of Health Services12. 
 
Cannabis Impairment 
 Cannabis impairment is the result of the psychoactive nature of the main ingredients of 
cannabis, chemical compounds called cannabinoids. Although there are over 60 cannabinoids 
found in Cannabis sativa, the cannabinoid that is primarily responsible for its psychoactive effect 
and is the most widely studied is Δ9-tetrahydrocannabinol (Δ9-THC or THC)13. THC interacts 
with cannabinoid (CB) receptors that are present in the brain and outer tissues, such as in the gut, 
resulting in behavioural and physiological effects that constitute cannabis impairment14, shown 
in Table 1. However, there is evidence that THC also has multiple non-specific effects on a 
number of neurologic systems and affect various enzyme systems and endocrine systems, as well 
as additional neurological pathways, which can make the effects of cannabis impairment highly 
variable between individuals and different strains of cannabis14. 
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Behavioural Effects Physiological Effects 
Euphoria Changes in heart rate and blood pressure  
Relaxation Red eyes 
Altered time perception Dry mouth and throat 
Lack of concentration Increased appetite 
Impaired learning Decreased respiratory rate 
Table 1. Behavioural and physiological effects of cannabis. Adapted from Sharma, Murthy, and Bharath, 201214. 
It has been argued that there is a lack of evidence relating to cannabis impairment15; this 
is partly true. It is true that the prohibition of cannabis has made it intensely difficult for 
researchers to study cannabis impairment in any meaningful way. However, it is more accurate 
to say that there is a lack of good quality evidence, as there are many studies that have been done 
that are subject to the social biases emanating from an era of drug prohibition4. The result is 
studies of cannabis impairment which rarely reflect how cannabis is actually used by those who 
use cannabis, and face methodological biases which blur the current scientific understanding of 
cannabis impairment4. 
A review carried out on the state of evidence of cannabis impairment as it relates to 
driving4 argues these same points. When those studies are looked at alone, it is clear that 
cannabis use does result in physical impairment, including short-term negative impacts on 
reaction time, motor coordination, divided attention, short-term memory and decision-making4. 
However, those impacts are not nearly on the same magnitude as impairment effects of other 
drugs, including alcohol, as measured by Odds Ratios (ORs) of increased motor vehicle 
accidents (MVAs). 
  The most comprehensive and recent review of this finding was done by Rogeberg and 
Elvik16 in a meta-review that was based on 21 studies, for a total of 28 estimates and a combined 
sample size of 239,739, of which 92% of the samples were from studies which reported 
estimates that were adjusted for known confounders. It addressed methodological problems with 
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previous meta-analyses17,18 including small sample sizes, pooling incomparable effect estimators 
(OR and culpability), failure to adjust for confounders, and use of measures that did not indicate 
current or recent cannabis use, and therefore would not reliably indicate impairment16. The 21 
studies included in the meta-review are shown in Table 2. 
The meta-review found that the pooled OR for MVAs for those who drove after using 
cannabis was 1.22 (1.1-1.36) based on a weighted least-squares meta-regression model, which is 
better able account for the biases of small sample sizes. This is much lower in magnitude than 
alcohol, which has an OR for MVA risk of 2-4 for blood alcohol concentrations of 0.05-0.08%19, 
or even other prescribed medications such as benzodiazepines, which has an OR for MVA crash 
risk of approximately 1.720. 
While these studies are in the context of cannabis impairment and driving, they are likely 
a reasonable comparison to how cannabis impairment would affect the risk of workplace 
accidents through worker impairment, as many of the same skills required for driving are 
necessary when performing potentially dangerous activities in the workplace as well. There is no 
comparable research in the field of occupational health and safety that investigates the risk of 
workplace accidents due to cannabis impairment, which is a significant gap in our understanding 
of cannabis impairment in the workplace. 
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Measurement of Cannabis Impairment 
 Perhaps one of the reasons that policy-makers struggle with measuring cannabis 
impairment is because of the previous experience with alcohol – in contrast to cannabis, alcohol 
is relatively easy to measure. Alcohol has one active ingredient, is water-soluble, and is therefore 
expelled from the body in a reasonably predictable pattern21. Additionally, its solubility in water 
means that the concentration of alcohol which is expelled from the breath can be used with a 
high degree of confidence to calculate the concentration of alcohol in the blood, and make direct 
inferences about an individual’s level of impairment21. This is the basis for measuring alcohol 
impairment in drivers around the world. 
 However, cannabis is not nearly so simple. While THC is believed to be the main active 
ingredient in cannabis, it is not the only one, and there is increasing research that suggests that 
the many other chemicals found in cannabis also play a role in how THC is absorbed and 
metabolized22. The concentrations and combinations of these many different chemicals vary 
between strains of cannabis22. Cannabis is also administered in a variety of ways, including 
smoking, vaping, oral ingestion of various forms, and topical applications, each of which 
distribute cannabis throughout the body differently. THC, unlike, alcohol, is fat soluble, which 
means that once it enters the body it is absorbed in fat cells, then slowly released back into the 
bloodstream as it is metabolized. Inhalation of cannabis results in a very fast uptake of THC and 
more rapid onset of psychoactive effects, usually within 1-2 hours, while ingestion of cannabis 
results in peak absorption of THC around 3-4 hours after use, and a slower metabolism4 (see 
Figure 2). All of these factors make it difficult to determine the exact effects of cannabis on 
impairment based on a biological measurement of a single component of cannabis, usually THC. 
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Figure 2: Diagram of absorption patterns of THC for smoked and orally ingested cannabis23. 
 
Figure 3: Diagram of mean urine concentrations of THC and its metabolites after smoking a cannabis cigarette 
containing 27mg of THC (N=8)24. 
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 However, despite the challenges in measuring cannabis impairment, there are still 
existing methods to doing so. One method which bypasses the problems of biological tests is 
behavioural-based impairment testing – in the context of driving, this is a Standardized Field 
Sobriety Test (SFST) which is carried out by a police officer. However, these tests were 
developed for alcohol impairment testing, and a review of evidence shows that they are not 
effective at predicting cannabis impairment, which present with different physical impairment 
characteristics than alcohol4. Police also have trained Drug Recognition Experts (DRE) who use 
a standardized set of behavioural and physical tests to determine drug impairment, however, 
these tests have also been shown to have a low effectiveness in identifying cannabis 
impairment4, and the testing and certification of DRE officers limits their widespread use. 
 For biological measures, a number have been used in research and in other forms of drug 
testing. Urinalysis is a widely-used measure, however, there are challenges with using this 
method as a determination of actual impairment by cannabis. THC is expelled in urine only after 
it is metabolized, and THC metabolites (typically 11-OH-THC or THC-COOH) can be detected 
in urine in high concentrations hours after initial use (see Figure 3 for a diagram of THC 
metabolism in urine after smoking), and research shows it may be present for up to days or 
weeks after it was initially absorbed25. This means it says nothing about impairment at the time 
the sample was collected, or even current use. 
 There is a growing body of research into other easily collectable biological samples, 
including breath and oral fluids26. While there is promise in these fields, the technology is still 
being tested and validated. For oral fluids, based on current research it appears that while levels 
of THC in oral fluid are not a good indicator of level of impairment (similar to breathalyzer 
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testing for alcohol), it is a good predictor of current use of cannabis, which is likely to indicate 
some level of impairment4. 
 The most accurate measure of cannabis impairment is blood testing for THC. Much 
research has been done to try to determine a blood THC level comparable to blood alcohol 
concentrations that are used to indicate driving impairment. While it is still an imperfect measure 
(as discussed above), current knowledge of cannabis impairment indicates that a blood level of 
THC of 7-10ng/mL in serum is a reasonable comparison in terms of level of impairment to BAC 
of 0.05-0.08%, a level used in may jurisdictions (including BC) to indicate alcohol impairment25.  
Methods 
 This paper uses a jurisdictional analysis approach in order to examine policy options for 
drug testing in the workplace in three different jurisdictions – US (federal), Colorado, and Maine 
– in comparison to relevant policies in BC. These jurisdictions were chosen for analysis due to 
their differing approaches to drug testing in the workplace, despite similar North American 
contexts. As the central argument of this paper is that a workplace policy for cannabis needs to 
balance the workplace safety with the potential of workplace policies to perpetuate social harms 
based in drug prohibition models, these jurisdictions will be compared on aspects relating to 
human rights as well as worker health and safety. Criteria used to focus the discussion of these 
policies are defined in Table 3. 
 Information on the different policy options in each jurisdiction were found online on 
governmental websites and through internet searches for supporting guidelines, policy 
interpretations, and relevant case law. Grey literature was used as a starting point to 
opportunistically identify materials that were relevant to the analysis.  
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Human Rights Worker Health & Safety 
How is testing carried out (i.e. is it random, 
mandatory)? 
What is the level of tolerance for cannabis in the 
workplace? 
Are there guidelines for those using cannabis for 
medical purposes? 
Are there guidelines or standards for consistent 
implementation of testing? 
Does the policy respect worker’s freedom to use 
cannabis when not at work (and when it will not 
affect their work?) 
What type of testing is done?  
What are the repercussions of a positive test? 
How accurate is testing as determining 
impairment? 
Table 3. Criteria for evaluating cannabis workplace drug testing policies with respect to human rights considerations 
as well as workplace safety. 
Results 
Description of Jurisdictions 
Each of the jurisdictions examined for this paper differ slightly in their approach to cannabis 
policy, which in the US adds confusion to the issue of workplace drug testing as cannabis is still 
illegal under US federal law. In the US, states can opt out of federal laws, which in effect causes 
the federal government to lose its ability to enforce cannabis prohibition. Colorado was one of 
the first states to legalize personal use of cannabis in 2012, along with Washington. Since then, 
Colorado has been the focus of international attention as an example of the state-wide effects of 
cannabis legalization. Maine, in contrast, is relatively new to cannabis legalization, with 
regulations to make cannabis legal just coming into effect in January 2017. All of these 
perspectives are useful to compare to Canada, which is on the brink of legalization and 
regulation of cannabis. 
 The distinction between cannabis legality at the federal level and state level in the US 
results in a complicated legal environment for drug testing in the workplace. Since cannabis is 
still illegal at the federal level, workers who are employed by federal organizations must still 
comply with federal workplace drug policies. Workers employed in the Department of 
Transportation (DOT) are required to undergo random testing if they are in what is considered a 
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safety sensitive position. This includes workers such as pilots, school bus drivers, ship captains, 
and any driver who holds a commercial driving license27. 
 At the state level, workplaces where federally-regulated employees work must have a 
DOT drug testing program in place for those employees. However, for other employees, and 
other workplaces, in neither Colorado nor Maine is drug testing required or prohibited. So, while 
under the federal Drug-Free Workplace Act employers must not allow impairment at work, drug 
testing is not a mandatory component of meeting that legislative requirement. This is similar to 
BC, where drug testing is also not required, and is in fact only permitted under BC Human 
Rights Code when there can be shown to be a Bona Fide Occupational Requirement (BFOR), 
such as in safety sensitive positions28. 
Test Implementation 
Human Rights  
How testing is carried out in each jurisdiction impacts human rights, as testing can be 
considered an invasion of privacy, both at the point of sample collection and when the sample is 
analyzed, as it reveals information about an individual which in most cases individuals have a 
right to keep private (such as other medications that the employee is taking, which may reveal 
other health issues). Testing procedures that are more stringent, which occur at a higher 
frequency and which require a more invasive sample (such as urine or blood) are greater 
restrictions on human rights, and therefore must not occur without undue reason. The most 
stringent testing procedure is done at the US federal level for DOT employees who are in safety 
sensitive positions, which emphasizes mandatory random testing. However, this infringement on 
human rights is considered justified under federal law based on the nature of the work that these 
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employees carry out, which has the potential to cause significant harm to other workers or 
members of the general public if they are in any way impaired. 
At the state level in Colorado and Maine, drug testing for non-federally regulated 
employees is not required; however, in Colorado, any employer can choose to implement a drug 
testing program without notifying the state. This means that a potentially greater number of 
workers are being subjected to drug testing without due cause. This issue is further aggravated by 
the fact that the Colorado Supreme Court has ruled that even though cannabis is legal at the state 
level, employers still have the right to terminate employees as the result of a drug test positive 
for cannabis, due to the overarching federal prohibition29, as happened to one Colorado worker 
who had been prescribed medical cannabis. In Colorado, not only does the policy framework for 
drug testing have the potential to subject workers to an invasion of privacy through testing where 
it may not be necessary, but this also forms the basis for discriminatory action against workers 
who are using cannabis legally. In Maine, drug testing for non-federally regulated employees is 
also optional, however state law is better equipped to deal with the challenges in Colorado’s 
approach as Maine employers must apply to the state to implement a drug testing program. It is 
reported that a small proportion of employers actually do so and get approved, with about 500 
out of 40,000 employers in the state performing any kind of drug testing, and fewer than 200 of 
which use random testing30. Those that do get approved for a drug testing program must follow 
state guidelines for testing protocols. This increases the likelihood that the invasion of privacy in 
the form of testing is only occurring where is it considered necessary for safety, and not 
impinging on human rights where there is no need. 
In BC, the drug testing situation is similar to Colorado and Maine, as implementation of a 
workplace drug testing program is optional. There is no requirement to report drug testing 
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programs to a regulating agency, as there is in Maine, or any requirement to meet certain drug 
testing protocols. However, unlike in Colorado, there are protections against unnecessary 
workplace testing in BC under the Human Rights Code28. In BC, courts have ruled that drug 
testing can only take place if there is reasonable cause or a near miss, and if it can be shown that 
there is a BOFR (such as a safety-sensitive workplace)28. Regular and/or random testing is only 
permitted for safety-sensitive workplaces, and only where the test indicates current impairment28.  
Worker Safety 
 The DOT guidelines for drug testing in the workplace argue that mandatory, random 
testing is the most effective way to prevent workplace impairment, as it acts as a deterrent for 
workers to be at work impaired27. This logic is justified under federal law for safety-sensitive 
positons, as the potential consequences of a safety-sensitive worker being impaired at work are 
severe. It is likely that this is true, and that the potential consequences of being caught with a 
positive drug test do prevent many workers from using drugs. However, as will be discussed 
further in the following section on testing protocol, the use of urinalysis for the mandatory tests 
reduces the effectiveness of the tests at detecting actual impairment. The end result of the DOT 
testing random procedure is to eliminate all drug use, including that of workers who use cannabis 
in their off-work time, which does not impact worker safety; and in the case of some workers 
who may be using cannabis for medical purposes, may make them less capable of performing 
their job.  
 The lack of guidance from Colorado on when and how workplace drug testing should be 
done is also an ineffective method of protecting worker safety. Without guidance on how a 
testing program should be carried out, employers may not have policies or procedures in place to 
be able to effectively use testing when it may be useful (for example, in case of suspicion of 
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impairment at work or after an incident). Maine, in contrast, does implement drug testing more 
effectively by having employers apply to the state to have a drug testing program, which ensures 
consistency of drug testing programs. While it means that fewer employers use drug testing, 
those that do are more likely to have policies and procedures in place to effectively protect 
worker safety. 
 In BC, there is also a lack of guidance on how drug testing should be carried out. What 
rules do exist have been settled by case law rather than guidance on what is most effective at 
protecting worker safety in balance with human rights. As is demonstrated in Maine, there is an 
opportunity to develop guidelines and to regulate when drug testing is necessary, which has the 
potential to increase the consistency and effectiveness of workplace drug testing. 
Testing Protocol 
Human Rights 
The protocol for workplace drug testing is an important consideration because, as 
discussed in the critical literature review, different tests have varying effectiveness of detecting 
actual impairment. The use of a test that in which a positive result does not indicate impairment 
or recent use is problematic in the context of personal freedom because it results in undue 
sanctions to an employee that are based on past use of cannabis, not on use of cannabis that 
would cause impairment at work. There is no scientific evidence that past cannabis has any 
lasting impairment effect that would prevent an employee from doing their job safely, except in 
extreme cases of cannabis dependence4.  
Unfortunately, this is a weakness of workplace drug testing programs in all jurisdictions 
analyzed for this paper. The most common type of drug testing used is urinalysis across all 
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jurisdictions. This is due to the relative ease of sample collection and available analytical 
methods for testing the presence of a variety of drugs in urine. However, THC can be detected in 
urine for a long period of time after initial use25, and effectively says nothing about impairment. 
Using this type of testing methodology effectively prevents workers from being able to ever use 
cannabis, even outside of working hours, placing a severe restriction on personal freedom. 
At the US federal level, some agencies of the DOT in certain circumstances (such as in 
response to an incident) do require the collection of other samples, such as blood. Blood is a 
much more accurate measure of current impairment than urine, although the nature of a blood 
sample makes it more invasive. Requiring a blood sample in extenuating circumstances where a 
measure of current impairment is of vital importance is balance between intrusions of a worker’s 
personal privacy and the consequences of using an inaccurate test; while in an ideal world the 
most accurate test would be used in all instances, it is unreasonable to require employees to give 
regular blood samples without due cause. 
In Maine, the guidelines for workplace drug testing set for employers includes cut off 
levels for a number of biological samples, including urine, hair, oral fluids, and sweat31. Of 
these, oral fluids is believed to be the most accurate at detecting recent use of cannabis, which 
may predict impairment but does not on its indicate impairment4. However, urine is still the most 
commonly used test. Additionally, the use of testing for THC in hair and oral fluids has not yet 
been validated as viable methods of testing current impairment. Overall, while Maine does 
provide guidance on the type of testing that should be used, the guidelines lack specificity, and 
even while meeting them employers may be implementing drug testing programs that are not 
accurate at detecting current impairment. 
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Colorado and BC both lack any guidance of what type of drug testing should be used in 
the workplace, and as such urinalysis is most often used by default. As a result, workers in these 
jurisdictions who do have to comply with drug tests are likely to be facing drug tests that impede 
their personal freedom to use cannabis in a way that does not affect their ability to work. In 
Colorado, the consequences of this are perhaps more severe, as workers can be terminated from 
employment based on a positive test. 
Worker Safety 
 Using a test that does not accurately measure impairment is not just a problem relating to 
human rights, but also impacts an employer’s ability to effectively address worker safety. As a 
testing methodology, urinalysis lacks specificity at identifying the outcome that actually matters 
for workplace safety, which is impairment, not simply the presence of THC. In other words, it is 
an ineffective tool at achieving the desired outcome of a safe workplace that is free of 
impairment. Along the same lines, testing hair and sweat samples as is described by the Maine 
drug testing policies for employers is also not proven to be effective. While blood testing is, with 
current understanding, the most effective at determining current impairment, it is impractical to 
implement due to the invasiveness of taking a blood sample. Oral fluid testing is believed to 
indicate recent use of cannabis, which is when workers are most likely to be impaired – however, 
it on its own does not indicate a level of impairment in an individual.  
Medical Cannabis 
Human Rights 
 One area in particular where human rights is an important consideration is the inclusion 
of workplace drug testing policies relating to workers’ use of medical cannabis. This issue is 
complicated by the fact that due to a lack of high quality scientific research in the area of medical 
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cannabis, there is a blurred line between what constitutes medical cannabis use and what is 
personal cannabis use, and what is an approved use of medical cannabis differs in each 
jurisdiction. Additionally, individuals may use cannabis in a way similar to self-medication, for 
example to help with stress or anxiety, and consider that to be medical use even if it is not an 
approved use in their jurisdiction. 
 From the perspective of human rights, in almost all jurisdictions, an employer cannot 
place restrictions on an employee based on medical reasons, including what medications they 
take. However, at the US federal level, cannabis is still a Schedule 1 drug with no approved 
medical uses. Therefore, there are no concessions for workers to use medical cannabis in DOT 
safety-sensitive positions. In Colorado, case law has determined that the overarching illegality of 
cannabis means that even if an employee is using cannabis for a medical use that is approved in 
Colorado, the employer still has the right to terminate employment of that employee if they fail a 
drug test. 
 Maine and BC both do not have any specific concessions for how to deal with medical 
cannabis use in relation to workplace drug testing. It is likely that if a conflict were to arise it 
would be dealt with on a case by case basis in the judiciary system. This is less than ideal, as it 
leaves a lot of uncertainty for those using cannabis for medical purposes on what they can or 
cannot do, and as a result they would likely not discuss their medical needs with their employer. 
Workplace Safety 
 One of the major questions of most employers as well as workers is whether using 
cannabis for medical purposes results in the same concerns of impairment as using cannabis for 
personal use. Fortunately, there is a scientific basis to answer this question. The most important 
component to answering this question is the mode of administration of cannabis. Most approved 
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medical uses of cannabis are administered orally (i.e. tablets, liquid drops), which behaves very 
differently in the body compared to smoking cannabis, as discussed in the literature review. In 
this instance, medical cannabis can be treated just as any other prescription medications, such as 
opioids or benzodiazepines are treated, in which patients are advised by doctors to monitor their 
own impairment especially when trying a new dose or strain. In effect, medical cannabis use can 
be managed to reduce the symptoms of impairment as the body builds tolerance to the 
psychoactive effects – and having an open discussion between the worker and employer in which 
a worker can give forewarning of when they may not be able to perform safety sensitive tasks 
due to medication changes would allow employers to accommodate those needs within a safe 
workplace. However, having guidance for employees to discuss their medical cannabis needs is 
not present in any of the jurisdictions which were analyzed for this paper. 
Discussion 
 In the face of legalization and regulation of cannabis in Canada, impairment in the 
workplace is (along with driving impairment) cited often in the media as one of the top concerns 
of the public and employers. Other jurisdictions, such as Maine and Colorado, which have 
legalized cannabis faced similar pressure to ensure that cannabis impairment did not become a 
widespread issue of public safety. 
 This is an interesting example of how risk perception often differs from objective 
measures of actual risk. The idea that cannabis legalization will result in mass uptake by the 
general population of cannabis has been shown to be unfounded in states where legalization has 
occurred, even in Colorado, where legalization of personal cannabis use has been in place for a 
number of years and has since been allowed to commercialize32. The advocacy efforts of the 
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medical cannabis community, changing perceptions on the effectiveness of a prohibitionist 
approach to drug policy, public acceptance of drug use, and lack of enforcement in many 
jurisdictions (especially some areas of BC, such as Vancouver) means that those who wish to use 
cannabis for personal use likely already do so. 
Additionally, there is in many cases a severe overestimation of the magnitude of the risks 
relating to cannabis impairment, which is based in a lack of understanding of the scientific 
evidence that is available, and perpetuated by the history of drug prohibition which framed 
cannabis - along with all other drugs - as extremely dangerous, and painted drug users 
themselves as reckless and aggressive outcasts of society10. In reality, the evidence shows that 
cannabis impairment, while it is still a problem in public safety contexts such as driving and the 
workplace, is in terms of magnitude a lower risk compared to other drugs which are legal, 
including alcohol and many prescription drugs. There is also a prominent cannabis culture which 
is very interested in promoting safe and healthy use of cannabis, which maximizes the benefits of 
cannabis use (such as socializing, relaxation, and treatment of minor illnesses such as pain) while 
doing so in a safe manner. It is short sighted of policy makers to continue to view cannabis as a 
one dimensional and dangerous drug that should be controlled, and in their best interest to 
recognize that cannabis use is as multi-faceted and diverse as the people that use cannabis, and 
work towards managing use that is problematic in partnership with those who cannabis rather 
than focus on prohibition. 
 In the context of workplace drug testing policy, the jurisdictions analyzed in this paper 
fall short of delivering a policy approach that reflects a balance between actual risk of cannabis 
impairment with considerations of human rights. Federally-regulated workers in safety-sensitive 
positions face the most stringent drug testing policies, although it can be argued that this is a 
24 
 
justified intrusion on human rights in the context of the consequences of impairment in those 
positions. At the state level, Colorado’s workplace drug testing policy appears to be 
dysfunctional at best, conflicting with the federal status of cannabis as a Schedule 1 drug. Maine, 
on the other hand, has made a move to protect a worker’s right to use cannabis outside of work 
by including in their regulations protections for workers against wrongful termination or refusal 
to hire based solely on an individual’s cannabis use outside of work. However, while their drug 
testing program does better at controlling the impact on human rights by requiring employers to 
apply to the state to run a drug testing program, their use of urinalysis for cannabis drug testing 
is, like all other jurisdictions, a serious flaw from both a human rights and effective worker 
safety perspective. 
 While no single policy approach stands out as being a model that meets both human 
rights and worker safety requirements, the jurisdictional analysis presented in this paper makes it 
easier to see the gaps in current workplace drug testing policies in the context of legalization, and 
to put forward several recommendations for how to address those gaps in BC as Canada moves 
toward cannabis legalization and regulation. These recommendations are presented below: 
Recommendation 1: Development of a provincial oversight for the implementation of a 
workplace drug testing policy. 
 In Maine, employers have to apply to the state Department of Labor to be able to 
implement a workplace drug testing policy. This allows the state to control what the protocols for 
drug testing are. BC, like Colorado, does not provide provincial/state guidance on what drug 
testing protocols are accepted, which leads to lack of consistency on which drug tests are used 
and when they are used. With the approach of cannabis legalization and regulation, knowledge of 
which drug testing protocols are most supported by best practice is something that employers 
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will need as they begin to respond to the new legislation. Having a regulatory oversight of testing 
protocols ensures that there is no testing being done which does not effectively determine 
impairment, and would therefore be an unnecessary invasion of privacy and ineffective at 
actually promoting safety in the workplace. This role could be taken on by provincial bodies of 
workplace safety, including WorkSafeBC, or be associated with another regulating body. 
Recommendation 2: Develop guidelines for the appropriate methodology for drug testing 
in the workplace that recognizes the need effectively identify cannabis impairment 
 While some jurisdictions analyzed did provide guidelines for workplace drug testing 
protocol, a weakness in all jurisdictions was the reliance on testing methodology that does not 
accurately demonstrate impairment. Urinalysis has long been the standard for drug testing in the 
workplace, however, it reflects the principles of drug prohibition that a worker should never use 
cannabis, even outside of the workplace, in a way that has no effect on their ability to come to 
work unimpaired and perform their job safely. Blood testing for THC is the only biological 
measure that has been shown to accurately predict impairment, however, it is impractical to use 
on a regular basis due to the invasiveness of taking a blood sample. Oral fluid has been shown to 
predict recent use, but not provide insight on any level of impairment. While there is much 
research being done into alternative methods for biological testing of impairment, currently the 
available tools are imperfect. 
 In the context of cannabis impaired driving, the Canadian Government has proposed that 
oral fluid screening be administered at the roadside if there is a suspicion of impairment, as 
method of identifying whether cannabis has been recently consumed33. If this resulted in a 
positive test, then there would be further evaluation by a drug recognition officer or a blood 
sample. This could be a reasonable response in the workplace as well, where if an employee is 
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suspected of being impaired they are first required to undergo an oral fluid screening, before 
undergoing further evaluation in the event of a positive test. This recognizes that impairment is 
most likely to occur with recent use of cannabis, and that an oral fluid screen is a relatively non-
invasive method of determining whether recent use has occurred. If determining a more specific 
measure of impairment is necessary, such as potentially following an incident or a near miss, 
requiring a blood sample from that employee is likely a defensible action from a human rights 
perspective.   
 The guidelines should be specific about when and how often testing can occur: for most 
occupations, under BC Human Rights Code, random testing is not permitted. Testing should only 
be done if there is reasonable cause to suspect impairment and after an incident or near miss. 
Safety sensitive positions for which random testing may be permitted should be explicitly 
defined. Having specific guidelines which are provincially regulated allows for greater control 
over which tools are used in the workplace, ensuring that they are both acceptable under human 
rights considerations and effective at promoting workplace safety. 
Recommendation 3: Develop guidelines for employers on managing medication 
impairment at work, including medical cannabis. 
 None of the jurisdictions analyzed in this paper had specific guidelines on how to deal 
with medical cannabis a work, except to say that is was still considered illegal under US federal 
law. However, in BC, employers are required to accommodate workers’ medical needs under the 
BC Human Rights Code. Provincial guidelines should define specifically what is considered 
medical cannabis so there is no confusion with self-treatment with cannabis, which would still 
likely be considered personal use. 
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 Since medical cannabis is not the only medication which can cause impairment, it is 
important that these guidelines address the management of medication impairment as a whole. 
Medical cannabis, like other prescription medications, can cause impairment when there are 
changes to an individual’s medication regime, however typically patients experience little 
impairment effects. Guidelines that encourage open and non-judgmental communication between 
a worker and their employer about their health needs as it may impact their safety or that of 
others at work is essential to supporting a worker’s rights while protecting worker safety. 
 This is not to say that those using medical cannabis should be excluded from drug testing 
programs where they are implemented – it is still an important tool in determining whether 
impairment was a factor in, say, an incident or near-miss.  
Recommendation 4: Continue to evaluate and incorporate new technologies for 
measuring cannabis impairment, especially non-invasive methods. 
 With the imminent legalization and regulation of cannabis, developing a fast, accurate, 
and non-invasive method for testing for cannabis impairment has been a top priority in the 
context of cannabis impaired driving. There are a number of pilot studies being done to test new 
technologies in this area. If an approved technology was not financially inaccessible, it could be 
potentially incorporated into workplace drug testing programs. 
 Research on cannabis impairment is a rapidly growing field. Any guidelines that are 
developed should be flexible enough to respond to advances in knowledge of cannabis 
impairment, especially as regards to testing methods that are as non-invasive to personal privacy 
as possible.  
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Conclusion 
 This paper has used a jurisdictional analysis approach to examine the issue of workplace 
drug testing policies in the context of cannabis legalization and regulation in Canada. Through 
examining drug testing policies at the US federal level, in Colorado, and in Maine, it is clear that 
there are significant gaps in how workplaces are dealing with cannabis impairment from the 
perspective of human rights as well as their effectiveness at promoting worker safety. While 
human rights and workplace safety are two lenses through which these policies can be examined, 
they complement each other, and do not result in as much of a conflict as one might originally 
have thought. This shows that it is possible to have a policy that respects an individual’s right to 
use cannabis outside of the workplace, while having drug testing policies in place that prevent 
impairment while on the job. The recommendations presented in this paper reflect the values of 
the cannabis legalization movement, that drug users should not be subjected to social harms 
solely based on their drug use, and that drug use can be managed and done safely. But they also 
are a rational approach to workplace safety which reflects a realistic view of cannabis use, that is 
not a problem to be eliminated but one to be managed by effective tools and cooperation with 
workers who use cannabis rather than prohibition. 
 The process of developing a cannabis legalization and regulation framework in BC and in 
Canada is likely to be a long one, and it is doubtful we will get it right the first time. However, 
the approach used in this paper demonstrates that it is possible to learn from other jurisdictions in 
order to give our first shot the best chance of success. Workplace drug testing policy is just one 
piece of the larger legalization puzzle, but with proper consideration of human rights along with 
concerns of safety, it can hopefully be a model for approaching issues relating to cannabis 
legalizing and regulation in the future. 
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Reflection 
I chose the topic of cannabis impairment in the workplace because I wanted to bring 
together two different perspectives that I have had the privilege to experience, which I didn't 
think often were brought together. For the past three years, I've worked in the field of 
occupational health and safety at WorkSafeBC, an area which I personally think is one of the 
most critical to public health.  
However, when I was choosing a practicum, I was really interested in pursuing another 
interest of mine - drug policy, and specifically relating to cannabis. While I had always been 
interested in drug policy, cannabis in particular caught my attention when it became an election 
topic in the Canadian federal election of 2015, and with the election of the Liberal government 
became a real possibility. I saw this as an exciting time for public health because it signalled an 
opportunity for an evidence-based approach to drug policy, something which has up until now 
been lacking. 
As part of my practicum, I came to have a high appreciation for the importance of 
evidence-based research in drug policy, as basing policies in social biases has historically 
perpetuated social harms. However, these social biases still largely exist, despite the fact that 
cannabis is on the brink of legalization and regulation at the federal level. During my practicum 
and since then, I found I often encounter people who still view cannabis how it has historically 
been portrayed, as a dangerous substance, and one that people should be prevented from using. 
As the changes to cannabis policy loomed nearer, concerns of how these policy changes would 
affect public became more common in news reports and in grey literature – including concerns 
from the world of occupational health and safety. 
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Having come from a background of occupational health and safety, and having 
researched cannabis impairment during my practicum, I knew that these concerns were valid – 
however, they are also inflated by historic biases which portray cannabis as inherently dangerous 
and morally wrong. I wanted to address these concerns while balancing them with a perspective 
that acknowledged these biases, as the evidence shows that these biases only lead to 
prohibitionist policies which are ultimately ineffective at achieving their goal. And, in my 
opinion, a policy that is based in multiple perspectives is more likely to be effective.  
I found that trying to balance different perspectives was challenging at times, but I think 
that in the end, both frameworks complement each other. While there is still a need for a great 
deal of research on cannabis, there is enough of an evidence base to at least make evidence-
informed policy decisions.  
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